Dr. Peter Buchwald, director of the DRI’s drug discovery program, was recently elected as a Fellow in the American Association for the Advancement of Sciences (AAAS) , the world’s largest scientific society. Dr. Buchwald received this prestigious appointment for his “distinguished contributions to the pharmaceutical sciences, particularly in the area of multi-disciplinary approaches to drug design and delivery utilizing computer-aided applications,” state the AAAS. Fellows are elected by their peers for their scientifically or socially distinguished efforts to advance science or its applications.
“Receiving this honor was a very pleasant surprise,” said Dr. Buchwald, who, together with 401 newly-elected fellows, was officially pinned on February 14 at the AAAS’ 2015 Annual Meeting in San Jose, CA.
Dr. Buchwald’s research is focused on small molecule drug discovery for immune-modulation with the goal of advancing the treatment and cure of type 1 diabetes.
“The long-term goal for our current research is to prevent diabetes or reverse the onset of the disease as well as to help those who have already received a pancreas or islet cell transplant,” said Buchwald.
The AAAS is an international non-profit organization dedicated to advancing science around the world by serving as an educator, leader, spokesperson and professional association. It also publishes the journal Science, as well as many scientific newsletters, books and reports, and spearheads programs. The AAAS serves 262 affiliated societies and academies of science, involving 10 million individuals.